Largest Ever Study on Marijuana Reveals Smoking It does not Damage the Lungs, Rather Improves It

Largest Ever Study on Marijuana Reveals Smoking It does not Damage the Lungs, Rather Improves It

http://anonhq.com/largest-ever-study-marijuana-reveals-smoking-not-damage-lungs-rather-improves/

We have said in the past, and still stand by it, that our goal is to promote medical use of marijuana, similar to the ones on CBD UK. We are not just an advocate of the plant just for smoking sake. We want people to benefit from it.

But across the world, there are many negative stereotypes and false mythologies about the plant. Especially in some countries in the global south; it is believed the mere smoking of marijuana irrespective of the quantity and the strength, can cause mental illness, the worst of it being madness.

However, over the years, as proponents of the plant gain momentum on its medical benefits, many researchers are using their own resources to conduct studies on the plant. Although research on the plant is still low, the little studies conducted are showing that some of the negative stereotypes against the plant aren’t true.

s 2

In the study we have come across on marijuana, it revealed that smoking the plant does not hurt the capacity of the lung, as previously suspected by medical experts. The study was conducted in 2012. It is said to be the largest ever study conducted on marijuana smoking. The study has been accepted in the Journal of the American Medical Association.

According to the study, even though most marijuana smokers tend to inhale deeply and hold the smoke in for as long as they can before exhaling, the lung capacity didn’t deteriorate, even among those who smoked a joint a day for seven years, or once a week for 20 years.

The study was conducted by researchers from the University of California, San Francisco, and University of Alabama at Birmingham, all in the United States.

The researchers said they knew tobacco smoking causes lung damage, leading to respiratory issues such as chronic obstructive pulmonary disease. However, they wanted to be clear whether smoking marijuana can also have similar effects as tobacco.

s 3

The researchers carried out their research by measuring lung function multiple times in more than 5,100 men and women during a 20-year period.

The data used in the study was from the Coronary Artery Risk Development in Young Adults. The researchers collected repeated measurements of lung function and smoking from March 1985 to August 2006. More than half of the participants, about 54%, said they were current marijuana smokers, cigarette smokers or both when the study began. The average marijuana use was only a joint or two a few times a month.

The researchers then calculated the effects of tobacco and marijuana separately, both in people who used only one or the other, and in people who used both. The researchers also considered other factors that could influence lung function, like air pollution in cities.

To know the healthiness of the lung of participants, the researchers measured how well participants could blow air in and out. It is said healthy adult can exhale about a gallon of air in one second.

Although the study focused on lighter smokers of marijuana and tobacco, the result showed that some participants who smoked more than a joint a day of marijuana for seven years could exhale even more than a gallon of air a second.

s 4

On the other hand, cigarette smokers struggled to exhale half a gallon, highlighting how cigarette smoking damages lung function, unlike marijuana smoking which has been shown to improve it. For those looking to quit smoking, you can find effective support at sites like https://heysnus.com/el.

However, the researchers warned that people should not simply take the findings of the study as a green light to smoke marijuana. They recommended that other factors should be considered before the plant is smoked.

“Marijuana is a complicated substance, and for people who are thinking about what they’ve done in the past or are thinking about using marijuana or believing it can help medically, their decision should not be based on lung consideration. It’s not a decision about lung health, it’s all the other issues: the risk of addiction, an increase in the chance of having accidents and social functioning,” co-author of the study, Dr Stefan Kertesz said. Dr Kertesz is also a researcher and primary care doctor at University of Alabama at Birmingham and the Birmingham Veterans Affairs Medical Center.

s 1

Dr Kertesz also added that the extra strength of the lung of marijuana smokers may come from the habit of deeply inhaling, holding and slowly exhaling the marijuana smoke. He said: “It’s a tiny increase; it’s not a big increase to lung health. So be careful not to say that, ‘Oh, wow! Lungs work better on marijuana.’ That would be totally inaccurate.”

Commenting on the study, Dr. Donald Tashkin, who has studied the relationship between marijuana smoking and lung function for more than 30 years as a professor of medicine at University of California Los Angeles said the study has confirmed what other research has also concluded on marijuana.

“This is a well-done study involving more subjects than in the past. The public should take away it’s a confirmatory study, but larger and longer than previous studies demonstrating, once again, that smoking marijuana does not impair lung function, unlike tobacco,” Dr Tashkin said.

 

 

How much would you pay to live pain-free?

How much would you pay to live pain-free?

https://www.washingtonpost.com/news/wonk/wp/2017/08/07/how-much-would-you-pay-to-live-pain-free/

What’s the dollar value of pain? Or more accurately: What’s the value of getting rid of it or avoiding it completely?

That’s the question posed by a team of Icelandic and American economists in a working paper published this week by the National Bureau of Economic Research. It’s not just an academic inquiry — the opiate epidemic currently ravaging many U.S. communities owes much of its existence to the more aggressive stance toward pain that pharmaceutical companies, doctors and patients started adopting in the 1990s.

The question of “how did we arrive at a place where 60,000 people a year die from drug overdose,” in other words, is at least partly a question of “how far would we go to avoid pain?”

But if you’re an economist, answering that question is surprisingly difficult. You can’t simply flat-out ask people how much they’d pay to avoid pain. Most people aren’t used to thinking of their suffering in dollar terms. People who haven’t experienced severe or chronic pain are likely to underestimate the value of being pain-free. There’s often a gap between what people say on questions like these, and what they actually do.

So for this paper, the researchers used a technique that’s been used to study the implicit “cost” of a number of different ailments, like migraines, cancer and arthritis. They analyzed data from over 22,000 Americans over the age of 50 who had taken part in the Health and Retirement Study, a federally-funded survey of older Americans, between 2008 and 2014.

That survey asked respondents three key questions. First, how satisfied they were with their life overall. Second, how much money they made in the past year. And third and most crucially: “Are you often troubled with pain?”

Triangulating a dollar value for pain from these three variables requires some statistical jiu-jitsu. To heavily oversimplify it, you can use the three numbers to estimate how much money it would take for a person currently suffering pain to rise to the same level of overall life satisfaction as somebody not experiencing pain. Conversely, for a person not experiencing pain you can estimate how much money you’d have to take away for them to have the same life satisfaction as a pain-sufferer.

As the study’s authors put it, you get an implicit answer to this question without having to actually pose it to people: “Consider your overall satisfaction with life being often troubled by pain, what would you be willing to pay to be just as happy but without pain?”

The answer: between $56 and $145. A day. Which works out to between $20,000 and $53,000 a year. Recall that the median household income is about $56,000, and the trade-off becomes stark: Some people would theoretically be willing to give up their entire livelihoods to be pain-free.

These results control for a number of other factors that could presumably influence this trade-off, like marital status, age, race, and various health conditions. The authors nonetheless found that two considerations have a lot of influence on the numbers: pain severity (the more pain you’re in, the more you’d pay to make it stop) and overall income (if you have more money to burn, you’d pay more to get rid of pain).

Still, the overall well-being cost of pain is staggering, particularly when you stack it against the cost of products designed to make pain go away: prescription opiates. At current prices, according to drug price aggregator GoodRX, you can purchase a 120-pill supply of Oxycodone for about $20 (without insurance). That works out to a generous day’s supply of four pills for a total of 68 cents. Insurance coverage would drive the price down to practically zero. All you need is a doctor’s prescription.

Imagine you’re a rational pain-sufferer, willing to pay upwards of $100 a day to ease your suffering. Along comes a product that offers the promise of doing that for less than 1/100th of that price. What are you going to do?

This new study has limitations, of course. It focused exclusively on older Americans — the math might be different for young folks. The pain price estimates are just that — estimates, based on survey data that may be subject to its own forms of error.

But it nevertheless underscores the huge gap between what people appear to be willing to pay to get rid of pain and the actual price dealing with pain via opiate painkillers.

Governor Cuomo: saving lives by making the lifesaving medication naloxone, more accessible and more affordable.”

First-in-the-Nation Program Offers Co-Payment Assistance For Medicine to Reverse Opioid Overdoses Beginning August 9, 2017

https://www.governor.ny.gov/news/governor-cuomo-announces-no-cost-or-lower-cost-naloxone-available-pharmacies-across-new-york

Governor Andrew M. Cuomo today announced a first-in-the-nation program to provide no-cost or lower-cost naloxone at pharmacies across New York. Beginning August 9, 2017, individuals with prescription health insurance coverage, including Medicaid and Medicare, will receive up to $40 in co-payment assistance, resulting in reduced cost or no cost for this lifesaving medicine. Uninsured individuals and individuals without prescription coverage will still be able to receive naloxone at no cost through New York’s network of registered opioid overdose prevention programs.

“This first-in-the-nation program will help put this lifesaving treatment in more hands and is one more prong in this administration’s efforts to battle heroin and opioid abuse,” Governor Cuomo said. “This is one more step toward a stronger, healthier New York for all.”

“Governor Cuomo has taken bold and aggressive action to battle the substance abuse crisis head on and today’s announcement furthers our attack on this epidemic,” said Lt. Governor Kathy Hochul, co-chair of the Governor’s task force to combat heroin and opioid addiction. “New York State is saving lives by making the lifesaving medication naloxone, which helps reverse the effects of an overdose, more accessible and more affordable.”

Naloxone is a medicine used to reverse opioid overdoses. Reducing the cost of this lifesaving medication builds on Governor Cuomo’s previous action to make naloxone available in pharmacies without a prescription which began in January 2016. Previously, New Yorkers could only receive naloxone with a prescription or through a registered opioid overdose prevention program.

As of August 9, 2017, New Yorkers can find co-payment information at pharmacy counters across the state and at: www.health.ny.gov/overdose. Individuals should provide this information to the pharmacist when asking for naloxone in order to receive it with no or lower out-of-pocket expense. The Naloxone Co-payment Assistance Program is funded by New York State’s Opioid Overdose Prevention Program.

Additionally, through New York’s network of registered opioid overdose prevention programs, uninsured individuals and individuals without prescription coverage will be able to receive naloxone at no cost. A full list of these programs is available here.

In the 2017 State Budget, Governor Cuomo invested over $200 million to fight the heroin and opioid epidemic. This unprecedented support is directed at prevention, treatment and recovery programs that address chemical dependency, expand residential service opportunities and promote public awareness and education.

Naloxone Saves Lives

Naloxone is a prescription medication used to reverse the effects of overdoses caused by heroin, prescription pain medication and other opioids. In 2014, state agencies began working together to develop a statewide program to train law enforcement personnel on how to administer naloxone. Since the trainings began, over 10,000 officers have been trained to administer the drug and 3,091 officers have been certified to train other officers. 

Trained law enforcement officers across New York are saving lives with the naloxone they carry. Since April of 2014, 2,036 officers have administered naloxone to over 3,100 individuals, saving the lives of nearly 90 percent of the individuals that required assistance.  

View a fact sheet on law enforcement naloxone training and usage, here.

New York State Department of Health Commissioner Dr. Howard Zucker said, “Naloxone is very effective at reversing opioid overdoses. Under Governor Cuomo’s leadership, New York State has taken comprehensive actions to stem the tide of opioid abuse, from increasing the number of treatment beds to making important health insurance reforms to eliminate barriers to accessing substance use services. The new copayment assistance program will make naloxone more available in communities across New York and save lives.”

New York State Office of Alcoholism and Substance Abuse Services Commissioner Arlene González-Sánchez said, “By guaranteeing affordable Naloxone to all New Yorkers, we will save thousands of lives and help repair the damage done to our communities by the opioid epidemic. Saving lives is the ultimate goal of all of our prevention, treatment, and recovery initiatives, and with this latest effort, Governor Cuomo is once again establishing New York State as a national leader in the field of addiction care.”

Chair of the Senate Committee on Alcoholism and Drug Abuse George Amedore said, “By increasing access to this effective remedy for drug overdoses, we are taking yet another step forward in combatting the heroin and opioid epidemic. I commend the Governor for removing barriers to help establish a stronger, healthier New York for generations.”

Chair of the Assembly Committee on Alcoholism and Drug Abuse Linda B. Rosenthal said, “New York’s communities are hard-struck by the heroin and opioid epidemic, and we must turn the tide by preventing more overdose deaths. Governor Cuomo’s plan to expand access to lifesaving naloxone through a new low-cost or no-cost co-payment system will help those struggling with this disease. By increasing access to Naloxone and cutting costs related to this lifesaving medication, New Yorkers in every corner of the state will be better equipped to save lives and help people receive the treatment they need. I look forward to working closely with the Administration to continue expanding access to overdose prevention and greater treatment options.”

Chair of the Senate Health Committee Kemp Hannon said, “The health and well-being of residents is our top priority. I look forward to working with the Governor to bring this treatment to our most vulnerable men and women, so that communities will be empowered to save the lives of thousands.”

Chair of the Assembly Health Committee Richard N. Gottfried said, “Health care is a right not a privilege, especially life-saving emergency treatment like naloxone.  I applaud Governor Cuomo’s commitment of public resources to help secure that right.”

Harm Reduction Coalition Medical Director Dr. Sharon Stancliff said, “This program will dramatically increase access to naloxone for people we haven’t easily reached. These include patients being treated for pain, loved ones of people returning from drug treatment or incarceration and people at risk in rural areas. This is a crisis and New York’s copayment assistance program adds to the solution.”

What To Do When Patients Press Record in the Emergency Department

http://epmonthly.com/wp-content/uploads/2017/08/PleasePutTheCameraDown-703x437.jpeg

What To Do When Patients Press Record in the Emergency Department

What To Do When Patients Press Record in the Emergency Department

Dear Director: It seems like more and more patients are trying to record me during my encounter with them. Sometimes it’s in the history portion, sometimes they want to record the procedure. I don’t want to end up going viral or get sued. Can I say no?

How many times have you seen friends post a picture of themselves or their family in an ER hospital bed? Technology has changed over the last decade, putting a high quality camera and recorder in everyone’s pocket, while social media has made it “normal” for people to post personal and private matters online. Thus, more of us are being confronted with a camera in our face as we perform our job in the emergency department. I was at a surgeon’s office last week, and there was a big sign at their registration window that said, “Absolutely no pictures or video recording.” I was afraid to even take a picture of the sign for fear that they would kick me out of the office, and I wouldn’t get the care that I need. There is no doubt we need to develop a policy that is in line with modern technology and social behavior.

Background
For decades, hospitals have been dealing with anxious parents as they want to record the birth of their child in labor and delivery. Interestingly, there are actually no national standards for allowing or not allowing recording equipment in the hospital, so each hospital must develop their own policy. And while patients or their families may say it’s their right to record themselves, that’s only true if they’re on their own property. Once they are on hospital property, patients and visitors must comply with hospital rules.

Motivation to Record
While I didn’t do this for my own kids, it does kind of make sense to me that people would want to make recordings in L&D. The motivation there is generally not to capture an error but rather to record a life-changing family event.

However, just like the family member who starts noting your time of arrival into a room and exactly how to spell your name before you even ask why the patient is there, you have to question why someone might want to record parts of their ED encounter. In this case, it’s likely that the family wants to document something because they assume something went wrong or will go wrong, or they’re already unhappy. My hospital rarely gets complaints about our video policy outside of L&D, so if someone wants to record something in the ED, your radar should be up. While a before and after picture of a laceration doesn’t bother me, it would be very bothersome to have a camera in my face while I’m actually doing my procedure. However, there can be some potential advantages of recording. Some physicians are encouraging patients to record the conversation about discharge instructions so that they can re-watch them if there are questions.

What’s There To Be Afraid Of?
The theory goes that if you’re doing everything right and practicing within the standard of care, there’s really no reason to fear a recording. But a camera and a recording can change everything. Although we work in a fishbowl and are used to “performing” at times for patients, most of us aren’t actors and we all should be focused on the patient and not focused on how we look, act, or speak on camera. Most of us come to work to take care of patients, not for the potential to be an Internet star. Probably most of us heard about the case where a patient turned on his phone recorder prior to a colonoscopy (with the intent of hearing discharge instructions), and then the anesthesiologist made insulting remarks about the patient. The procedure took place in 2013, and the malpractice case concluded in 2015. Clearly the doc wasn’t “doing everything right” and wasn’t professional, but the recording cost them in court and made them infamous.

Someone making a recording can also get in the way of caring for a patient. In areas of the hospital where a patient can worsen quickly and without notice (L&D and the ED), all eyes should be on protecting and caring for the patient – not on dealing with someone who may be in the way by making a recording.

Hospitals also have an obligation to protect the privacy of their patients (remember HIPAA?). Someone may be making a recording of their family member but then capture another patient in the process who does not want to be recorded and didn’t give consent. While TV news crews can film the outside of a hospital (with the normal people coming and going) from the sidewalk (considered public grounds), you typically won’t see news cameras inside the hospital without someone from your PR office carefully controlling the image and what’s visible so the rights of patient’s privacy are protected.

Physicians and hospital administrators are also concerned about how video may be used. It’s one thing to show a friend how goofy your teenager is after receiving meds from surgery; it’s another if it could be used for litigation. It’s so easy to edit recordings now that a chopped up sequence of events would not show the entirety of the situation and may not be a fair reflection of what happened. Thus, the recording could lose the true perspective of events.

Putting Aside Distraction
I filmed a commercial for a hospital years ago. I’ve had no acting experience since the sixth grade, but the script was simple, I had a teleprompter, and the director thought the whole thing would take a matter of minutes to film. An hour later, I was embarrassed to still be there (on some takes there were issues of the lights reflecting off my bald head and on other takes, I missed my mark when I was walking in) and ready to get back to the ED, but the director thought he finally had a good take. I never thought acting was easy, but this experience proved it to me. It also serves as a reminder about how as clinicians we need to focus on our jobs while not being distracted. Whether it’s a camera in your face or the perceived threat of a lawsuit, these are distractions that could interfere with patient care.

Next Steps
The hospital has an obligation to protect the facility, staff, physicians, and patients and doesn’t want to compromise any party. As with many administrative questions, the answer may lie in your hospital’s policy book. Get to know your policy on patients making recordings and make sure your policy is consistent with your work environment and concerns. While the policy may prohibit recording in L&D, it may not comment on the rest of the hospital or it may only prohibit it in L&D during the actual birth. If it doesn’t include the ED, now’s the time to work with your public relations department to come up with a set of rules that are applicable to the ED.

I would propose absolutely no recordings and no photographs that include staff or other people/patients in the ED. Unless it’s a big problem, I wouldn’t advocate putting signs at triage or in patient’s rooms. While I’m not likely to tell a patient not to take a selfie in the ED, I will ask them not to do it while I’m at the bedside. If a patient wants to record something it’s always helpful to be able to say that our hospital prohibits the use of recording devices. If you don’t have a policy, or if they argue with you, I suggest politely saying that this conversation is taking attention away from the patient and not helping the patient and that you don’t consent to being recorded. While I would never advocate walking away from a sick patient, if you have the luxury of time, I would step out of the room. If the family is recording because they’re afraid of a mistake or if there’s a grievance, you can have someone from patient relations come talk to them.

When All Else Fails
It may, on rare occasions, be necessary to call security. If someone continues to record in the ED against hospital policy, you have to remove them. While there are clear needs for hospital security when it comes to a violent patient, I think of calling security as a last resort in this situation, as it may further irritate a patient or family member in what is likely a volatile situation. Therefore, prior to calling security, make sure you’re doing it for the right reasons, which may include following policy, protecting your ability to take care of the patients without distraction, or protecting privacy.

Technology isn’t going away, and just like we’re starting to see more police officers with cameras attached to them, there certainly may come a time when we see more recordings of the physician-patient interaction. I can’t remember the last time a patient wanted to record my interaction with them or that someone in my group mentioned it to me, so for now, I still think we’re early in this evolution. Therefore, we can go ahead and work on developing policies with our administration that take into account some of the patients’ desires while protecting the hospital, staff, and other patients.

No matter the setting, all healthcare professionals “records” what goes on when dealing with a pt… it is called “the pt’s medical record” and unless there is something that proves or refutes what was actually done… then the healthcare professional’s beliefs, opinions, “lies” that are put in the pt’s medical record will be considered “the truth”.

Without a video/audio recording.. there can be three sides to every story… mine, yours and THE TRUTH. Without a audio/video recording… it will be the healthcare professional’s input in the pt’s medical record that will probably prevail.

Two of the three largest PBM’s to limit opiates

Express Scripts mail-order pharmacy to limit opioids

www.ktar.com/story/1696130/express-scripts-mail-order-pharmacy-to-limit-opioids/

The nation’s largest pharmacy benefit manager will soon limit the number and strength of opioid drugs prescribed to first-time users.

The move by Express Scripts, which has offices in Tempe, was part of a wide-ranging effort to curb an epidemic affecting millions of Americans.

But the new program has drawn criticism from the American Medical Association. The organization said doctors and patients should decide the course of treatment.

 Federal health officials reported that an estimated 12.5 million Americans misused prescription opioids in 2015, and about 33,000 people died from overdoses.

Express Scripts wants to limit prescriptions to seven days for first-time users and require short-acting opioids.

The Missouri-based company also wants to monitor for potential abuse. The program excludes hospice, palliative care and cancer patients.

A competitor, CVS Caremark, has a similar program.

Flimsy evidence behind many FDA approvals

Flimsy evidence behind many FDA approvals

https://in.reuters.com/article/us-health-fda-approvals-idINKCN1AV23K

(Reuters Health) – Many drugs granted accelerated approval by the U.S. Food and Drug Administration (FDA) lack clear evidence of safety and effectiveness, and the same is true for most high-risk medical devices, according to two new reports in the Journal of the American Medical Association.

The Accelerated Approval pathway makes potentially promising investigational medicines available for use before the usual amount of data has been collected to confirm their effectiveness and safety, Dr. Huseyin Naci from the London School of Economics and Political Science told Reuters Health by email.

“Drugs granted Accelerated Approval should be rigorously evaluated using convincing patient-centered clinical outcomes in rigorous studies,” Naci said. But, he added, “we have found numerous situations in which required confirmatory studies with rigorous designs and outcomes are not pursued or are not completed in a timely fashion, and in these cases, we are concerned that regulators appear to accept data that would not otherwise meet FDA standards.”

Naci’s team analyzed the FDA’s accelerated approval of 22 drugs for 24 medical conditions.

For standard approval, the FDA generally requires gold-standard randomized controlled trials (RCTs) that demonstrate a drug’s safety and effectiveness. Fourteen of these accelerated approvals, however, were exclusively based on less-rigorous trials.

Given the lower standard of evidence, the FDA required 38 more trials after approval to confirm the benefits of these drugs. Three years after approval, though, only 19 had been completed. Eleven more were underway and said to be on schedule, six others were delayed by more than 12 months, and two had been discontinued.

Most of these later trials still used outcomes that would not be acceptable for standard approval, and several studies failed to show a benefit or were terminated early.

For the 10 approvals that finally met the requirements established by FDA, the time to do so ranged from one to five years after the accelerated approval.

“Our findings suggest that expediency in drug development and approval can be successful but that drugs approved via the shorter route to market are rarely subject to tests even in the post-approval period that use established and clinically meaningful outcomes,” Naci said.

When the FDA approves medicines via its Accelerated Approval pathway, he said, the agency should clearly specify the data limitations and how required confirmatory studies are expected to compensate for these limitations.

A second report from Dr. Rita F. Redberg from the University of California, San Francisco, and colleagues paints a similar picture when approval is needed for modifications to high-risk medical devices.

“We expected to find generally high-quality evidence to support these changes, because these devices are important to health, and many are implanted and are difficult and/or dangerous to remove,” Redberg told Reuters Health by email. “We were surprised to discover that relatively few studies were randomized or blinded, which means that it is not known if the device was better than an alternative treatment (or better than no treatment), and whether any purported beneficial effect was actually due to the well-documented placebo effect of procedures and devices.”

“In addition, we were disturbed to find numerous discrepancies between the number of patients enrolled and the number of patients with data reported, indicating that there is loss (or incompleteness) of data evaluated by the FDA,” she said. “This raises concerns about missing data and selection bias.”

Of the 78 device modifications they studied, 71 were supported by a single clinical study, and half of these enrolled 185 or fewer patients. One in 12 studies did not specify what the researchers were looking to prove.

“I think the public assumes that medical devices currently on the market, particularly high-risk devices, have been approved based on a high standard to show safety and effectiveness before doctors can recommend and implant them,” Redberg said. “Our findings show that this assumption is often incorrect.”

Dr. Robert M. Califf from Duke University School of Medicine, Durham, North Carolina, who wrote an editorial related to these reports, told Reuters Health by email, “People should ask their doctors about the evidence for drugs and devices being prescribed or use, and they should support research and participate. In addition, they should encourage their doctors to participate; too many doctors just ‘go with the flow’ rather than demanding high-quality evidence about what they are prescribing and implanting, and actively joining into appropriate clinical trials.”

California Hospital Sued for Refusing to Assist Suicide

California Hospital Sued for Refusing to Assist Suicide

www.nationalreview.com/corner/450438/california-hospital-sued-refusing-assist-suicide

This lawsuit is a little before its time. Should assisted suicide become widely accepted in this country, activists will try to force all doctors to participate–either by doing the deed or referring to a doctor known to be willing to lethally prescribe. But it isn’t yet, and so the pretense of the movement that they only want an itsy-bitsy, teensy-weensy change in mores and law continues as SOP. But sometimes they show their true intentions. Thus, when UCSF oncologists refused to assist a cancer patient’s suicide, the woman died of her disease. Now, her family is suing–using the same attorney (Kathryn Tucker) who tried (unsuccessfully) to obtain an assisted suicide Roe v Wade in 1997 and has brought other pro-assisted sucide cases around the country. From the San Francisco Chronicle story: Judy Dale died of cancer in her San Francisco home in September, in agony, after being denied the pain-relieving medication she might have received under the state’s aid-in-dying law that had taken effect three months earlier. Bias alert! Pain relieving medication is palliative, to ease pain or other very uncomfortable. Dale was not issued a lethal prescription intended to kill her. That’s not the same thing. Back to the story: A lawsuit by her children will determine whether UCSF Medical Center, where Dale first went for treatment, was responsible for her suffering by allegedly concealing its oncologists’ decision not to provide life-ending drugs to patients who ask for them. More broadly, their suit illuminates the inner workings of a law that confers new rights on terminally ill patients, but few obligations on their health care providers. Specifically, doctors and hospitals are provided clear and explicit conscience protections in the law. No hospital or physician can be forced to participate or refer in an assisted suicide Demonstrating the disingenuousness of the lawyers bringing suit, that provision was–as the story reports–required to induce the California Medical Association to go neutral on the law, without which it almost surely would never have passed. The primary claim is elder abuse. If that theory prevails, not helping kill a patient would become a form of abuse! Unthinkable. The plaintiffs also contend that the hospital had assured Dale she would be able to receive assisted suicide, and then failed to follow through. I don’t know if that kind of statement would be actionable or not since there is no legal duty to do the deed, as it were. But this I do know: The lawsuit illustrates where the assisted suicide/euthanasia movement wants to go. As in Ontario, Canada, they want doctors and hospitals to be forced to participate in assisted suicide or get out of medicine.

 

CDC: the guideline’s recommendations reflected weak scientific evidence.

Strict limits on opioid prescribing risk the ‘inhumane treatment’ of pain patients

www.statnews.com/2017/02/24/opioids-prescribing-limits-pain-patients/

Amid a rising toll of opioid overdoses, recommendations discouraging their use to treat pain seem to make sense. Yet the devil is in the details: how recommendations play out in real life can harm the very patients they purport to protect. A new proposal from the Centers for Medicare and Medicaid Services to enforce hard limits on opioid dosing is a dangerous case in point.

There’s no doubt that we needed to curtail the opioid supply. The decade of 2001-2011 saw a pattern of increasing prescriptions for these drugs, often without attention to risks of overdose or addiction. Some patients developed addictions to them; estimates from the Centers for Disease Control and Prevention range from 0.7 percent to 6 percent. Worse, opioid pills became ubiquitous in communities across the country, spread through sale, theft, and sharing with others, notably with young adults.

The prescribing tide has turned: Private and governmental data show that the number of prescriptions for opioids has been falling since 2012. Reassuringly, federal surveys show that misuse of pain relievers bottomed out in 2014-15.

Nevertheless, the CDC produced a guideline in 2016 that recommended shorter durations for opioid prescriptions and the use of non-drug treatments for pain. It also suggested keeping opioid doses lower than the equivalent of 90 milligrams of morphine. As the guideline acknowledged, its recommendations reflected weak scientific evidence. Problematically, it was silent on how to care for patients already receiving doses higher than the 90 milligram threshold.

Unfortunately, these mitigating features were undermined by intemperate publicity that vilified opioids for pain. Opioids for pain “are just as addictive is heroin,” proclaimed CDC Director Dr. Tom Frieden. Such statements buttress a fantasy that the tragedy of opioid overdoses and deaths will be solved in doctors’ offices, primarily by upending the care of 5 to 8 million Americans who receive opioids for pain, even when most individuals with opioid addiction did not start as pain patients.

The progression of the guidelines from “voluntary” to “enforceable” has culminated in a draft policy from CMS. It would block all prescriptions above the CDC threshold of 90 milligrams unless complex bureaucratic barriers are surmounted. Many pharmacy plans are already enforcing this approach. Under that plan, many patients suffering with chronic pain would lose access to the medicines they are currently taking, all in the name of reversing a tide of death increasingly defined by non-prescribed opioids such as heroin and fentanyl.

The logic of doing this is untested. There have been no prospective clinical studies to show that discontinuing opioids for currently stable pain patients helps those patients or anyone else. While doing so could help some, it will destabilize others and likely promote the use of heroin or other drugs. In effect, pain patients currently taking opioids long-term have become involuntary participants in an experiment, with their lives at stake.

Turning the voluntary guidelines into strict policy is unfortunate for three reasons.

Second, we have alternatives to bureaucratic controls. These include promoting and paying for treatments that de-emphasize pills. Important work by the Department of Veterans Affairs shows how to identify patients with elevated risk for harm from opioids and how to mitigate the risks.

Third and most troubling is the increasingly inhumane treatment of patients with chronic pain. Fearing investigation or sanction, physicians caring for patients on long-term opioids face a dire choice: to involuntarily terminate prescriptions for patients who are otherwise stable, or to carry on as embattled, unprotected professionals, subject to bureaucratic muscle and public shaming from every direction.

In this context, we cannot be surprised by a flurry of reports, in the press, social media, and the medical literature describing pain patients entering acute withdrawal, losing function, committing suicide, or dying in jail. The CMS policy, if adopted, will accelerate this trend.

Many of our colleagues in addiction medicine tell us they are alarmed by the widespread mistreatment of pain patients. We receive anecdotes every week from physicians and pharmacists, most of them expert in addictions, describing pain patients who have involuntarily lost access to their pain medications and as a result have been reduced from working to bedridden adults, or who have become suicidal.

This loss of access occurs several ways. A pharmacy benefit program may refuse to cover the prescription because it has already enacted the changes that CMS is proposing to make mandatory. A physician may feel threatened by employers or regulators, and believes his or her professional survival depends on reducing opioid doses — involuntarily and without the patient’s consent — to thresholds that the CDC itself described as voluntary and not mandatory. Or state regulators have imposed such burdensome requirements that no physician in a given region can sustain prescriptions for their patients. Such patients are then “orphaned,” compelled to seek treatment from other physicians across the country.

Given the expertise in addiction among these physicians, it should be particularly worrisome that they believe the present pill-control campaign has gone too far. And yet, the ethics are clear: It should never be acceptable for us to countenance the death of one patient in the avowed service of protecting others, even more so when the projected benefit is unproven.

Surgeon General Dr. Vivek Murthy made an underappreciated declaration in a recent interview with the New England Journal of Medicine. “We cannot allow the pendulum to swing to the other extreme here, where we deny people who need opioid medications those actual medications. … We are trying to find an appropriate middle ground,” he said.

As addiction professionals, we agree wholeheartedly.

Oligoanalgesia in the emergency department

Oligoanalgesia in the emergency department

http://www.medscape.com/medline/abstract/2803357

Oligoanalgesia: Underuse of analgesics in the face of valid indications–eg, intense bone pain of terminal CA–for its use.

A review of the charts of 198 patients who were admitted through the emergency department with a variety of acutely painful medical and surgical conditions revealed that 56% received no analgesic medication while in the emergency department. In the 44% of patients who received pain medication, 69% waited more than 1 hour while 42% waited more than 2 hours before narcotic analgesia was administered. In addition, 32% initially received less than an optimal equianalgesic dose of narcotic when compared with morphine. This study demonstrates that narcotic misues, in the form of oligoanalgesia, is prevalent and is the shared responsibility of both emergency physicians and housestaff consultants.

New Ky. law limits prescriptions for certain pain meds to 3-day supply

New Ky. law limits prescriptions for certain pain meds to 3-day supply

http://www.wdrb.com/story/35790831/new-ky-law-limits-prescriptions-for-certain-pain-meds-to-3-day-supply

LOUISVILLE Ky. (WDRB) — A new law that limits how much pain medicine doctors can prescribe in Kentucky is now in effect. 

The new law that took effect Thursday is designed to help fight the opioid epidemic that’s sweeping the nation. Under the new law, prescription painkillers will be limited to a 3-day supply in an effort to prevent abuse. 

The idea behind HB 333 is to prevent extra opioid pain pills from entering the illegal drug market. The bill underwent intense debate by Kentucky lawmakers before it was passed earlier this year. 

The bill’s sponsors say the goal is to get drugs like fentanyl and carfentanyl off the streets and out of the hands of drug traffickers. Penalties for anyone caught trafficking the drugs are now elevated to a Class C Felony for a first offense. 

The biggest concern over the new law centers on the 3-day pain pill limit, which prohibits doctors from issuing a prescription for more than the three days for Schedule II narcotics like OxyContin. 

Some patients who truly need the medication say the law makes it too difficult for them to get pain medication for legitimate reasons. 

The law does include exceptions for cancer patients, people diagnosed with chronic pain and patients receiving end-of-life care.

  How bright does a politician have to be to come to the conclusion that by limiting the legal prescribing of opiates will somehow stop the flow of ILLEGAL OPIATES from being on the street ?